Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Study Details
Design, interventions, and primary outcomes
About This Study
This study will evaluate the safety, tolerability and efficacy of anlotinib and trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who had received ≤1 line of prior chemotherapy.
Design
Interventions / Regimen
- Drug: Anlotinib — Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
- Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Primary Outcomes
- Determination of the RP2D of anlotinib in combination with trastuzumab deruxtecan (up to 1 year)
- Objective Response Rate (ORR) (Up to approximately 3 years)
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-31
Completion: 2027-06-30
Sex: FEMALE
Volunteers: false
Enrollment: 42 (ESTIMATED)
- Drug: Anlotinib — Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
- Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.